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Objective: To analyze the factors associated with type 2 diabetes mellitus (T2DM)
“remission” in non-bariatric Medicare patients 65 years and older.
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Research Design and Methods: A retrospective cohort analysis of a Medicare
Advantage health plan was conducted using administrative data. An individual was
identified as T2DM if the individual had: ≥ 2 medical claims for T2DM coded 250.xx
excluding type 1 diabetes; or ≥ 2 pharmacy claims related to T2DM; or ≥ 2 combined
medical claims, pharmacy claims for T2DM in 12 months. A T2DM individual was in
“remission” if they had no T2DM related claims for more than 12 months continuously.
This is different from the standard American Diabetes Association (ADA) definition of
remission which includes HbA1c values and hence is represented in quotation (as
“remission”). 10,059 T2DM individuals were evaluated over a period of 8 years from 2008
to 2015. Cox proportional hazards was used to identify significant variables associated
with T2DM “remission.”
Results: 4.97% of patients studied met the definition of T2DM “remission” in the study
cohort. After adjusting for covariates this study found a number of variables associated
with T2DM “remission” that were not previously reported: no statin use; low diabetes
complications severity index score; no hypertension; no neuropathy; no retinopathy; race
(non-white and non-African American); presence of other chronic ischemic heart disease
(IHD) and females (p < 0.05).
Conclusion: T2DM “remission” in Medicare patients 65 years and older is observed in
a community setting in a small proportion of non-bariatric patients.
Keywords: diabete mellitus, Type 2 diabete mellitus, remission, bariatric, medicare, 65 years and older

Type 2 diabetes mellitus (T2DM) is generally considered as a chronic, incurable, progressive and
life-long disease condition. T2DM disease management focuses primarily on glycemic control and
management of the macrovascular and microvascular complications that may be associated with
hyperglycemia (1, 2). However, a growing body of evidence indicates that T2DM remission can be
achieved in certain individuals (3).
The American Diabetes Association (ADA) has defined the term remission as “. . . achieving
glycaemia below the diabetic range in the absence of active pharmacologic or surgical therapy.”
ADA classifies remission into one of the following three types: a) partial remission, defined as
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pharmacological factors associated with T2DM “remission” in
non-bariatric Medicare patients 65 years and older.

sub-diabetic hyperglycemia without active pharmacologic
therapy or ongoing procedures for at least 1 year. Subdiabetic hyperglycemia is characterized by HbA1c <6.5%
and/or fasting glucose 100–125 mg/dL [5.6–6.9 mmol/l]; b)
complete remission, defined as “normal” measures of glucose
metabolism without active pharmacologic therapy or ongoing
procedures for at least 1 year. Normal measure of glucose
metabolism is when HbA1c is in the normal range, <5.7%, <39
mmol/mol, fasting glucose <100 mg/dL [5.6 mmol/l]); and c)
prolonged remission, defined as complete remission for at least
5 years (4).
Current evidence on T2DM remission suggests that
there are at least two key approaches for T2DM remission
namely, metabolic/bariatric surgery and/or intensive lifestyle
management (1). Of these two approaches, bariatric (“weightloss”) surgery has been proved to be effective in treating T2DM
patients whose BMI is 35 kg/m2 or higher (5) with a success of
achieving T2DM remission between 24 and 95% (6, 7). Bariatric
surgery is considered relatively safe with 30 day mortality
between 0.1 and 1.1%. However, the risk of developing acute
complications and long-term complications is high (17%). The
rate of reoperation following bariatric surgery is around 7% and
patients are often required to have a close postoperative medical
monitoring (8–11).
Current understanding of T2DM remission among nonbariatric patients is very limited. A recent post hoc randomized
controlled study from the Look AHEAD (Action for Health
for Diabetes) and the 2014 Kaiser Permanente study have
shown metabolic/bariatric surgery is not the only pathway
to remission. Although rare, T2DM remission does occur
in certain non-bariatric populations (3, 12, 13). However,
very little is known about remission and factors associated
with it.
Understanding factors predictive of remission within the
Medicare patients 65 years and older is important because
Medicare population differs from population at large by their
age, life expectancy, and frequency of comorbidities (14), and
have a significantly higher prevalence of T2DM compared to the
population at large (15). Even though age itself is not a significant
differentiator for bariatric outcomes, the higher occurrences
of baseline comorbidities in the Medicare population might
make this population less suitable for bariatric surgery (16, 17).
Therefore, understanding these factors has substantial clinical
relevance to the design of interventions which lead to remission.
In addition, these data could be used to help design better T2DM
management programs.
In order to identify remission as per the ADA definition,
a researcher would need both pharmacy and laboratory
data (HbA1c ). However, laboratory test data are not always
available to researchers, especially to those researchers who
only rely on administrative claims data for their analytical
work (18). Therefore, a modified definition for remission is
offered in the present study. In this investigation, the modified
definition of remission is enclosed in quotation marks (as
possible “remission”).
In this study we estimate the rate of type 2 diabetes mellitus
(T2DM) “remission” and analyze demographic, clinical and
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RESEARCH DESIGN AND METHODS
Study Design
This study was a retrospective cohort analysis using Medicare
Advantage Prescription Drug (MAPD) health plan data. This
administrative data includes patient level enrollment, medical
claims and pharmacy claims data. These data were collected
during the standard operations of a large multistate healthcare
company. It was not originally collected for the purpose of
research or any new study of human or animal subjects. Prior
to the start of the study this study protocol was reviewed and
approved by the University of Louisville Institutional Review
Board. The study was also approved by the healthcare company’s
review board.

Study Cohort
The federal government offers original Medicare insurance,
which includes Medicare Part A (Hospital Insurance) and
Medicare Part B (Medical Insurance). Part C (or Medicare
advantage) are offered through private insurance companies. Part
C includes the benefits of Part A, Part B and sometimes the
optional Part D (prescription drug coverage) along with several
choices of programs and services specific to each Managed Care
Organization (MCO). Individuals can only be enrolled in Part
C if they qualify for Medicare part A and part B. An individual
may qualify for Medicare if they are at least 65 years old in the
year of their Medicare enrollment and meet certain additional
eligibility criteria. In addition, some individuals may qualify for
Medicare for other reasons such as disabilities or end stage renal
disease (ESRD). Individuals whose initial reason for Medicare
enrollment was either disability or ESRD were excluded from the
present study.
The large multistate healthcare company offers Medicare
Advantage Prescription Drug Plan (MAPD) a Part C plan, which
includes the benefits of Medicare Part A, Part B and Part D,
to individuals. The healthcare company insured more than 2.4
million individuals who had MAPD coverage from January 1,
2008 to December 31, 2015. Of these ≥ 2.4 million individuals
more than 1.7 million MAPD individuals had “age ≥ 65” as the
original reason for Medicare enrollment. The remainder qualified
under Medicare disability or ESRD eligibility provisions. Of
these > 1.7 million patients there were 265,554 patients who had
continuous MAPD coverage with the healthcare company from
January 2008 to December 2015.
The initial sample after the above exclusions of 265,554
patients, additional exclusions were: (a) individuals who had a
prior bariatric surgery (including gastric bypass, laparoscopic
gastroenterostomy) (n = 619); (b) individuals with polycystic
ovary syndrome (n = 131), and lipodystrophy (n = 718); (c)
individuals with any diagnostic codes related to nephropathy
were excluded because it indicates irreversible end organ damage.
In the current study, the nephropathy exclusion resulted in
excluding 41.3% of the study sample. Previous research suggested
that the rate of chronic kidney disease (CKD) in individuals
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codes only during inpatient hospital stay and did not have
T2DM diagnostic claims or T2DM related pharmacy claims in
a non-hospital setting were excluded to account for potential
surgery induced dysglycemia (n = 1,772); g) certain groups with
contractual restrictions with the health plan prohibiting research
(n = 2,238).
The definition of “remission” in this study was different from
that used by ADA, because of the lack of HbA1c data. An
individual was encoded as being in “remission” if they met the

who are 65 years and older was 61%. CKD rate in the current
study was likely lower because individuals with “disability”
and “ESRD” as their initial reason for Medicare enrollment
were excluded from the sample (19); (d) individuals who
had pharmacy claims related to drug and/or steroid induced
diabetes were excluded (n = 3,436); (e) individuals with type
1 diabetes were identified using ICD codes and excluded
because type 1 diabetes has a different etiology from T2DM
(n = 25,535); (f) individuals who had T2DM related diagnostics

FIGURE 1 | Inclusion and exclusion criteria.
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following criteria: (a) had two or more T2DM related claims in
previous years; (b) had no T2DM related claims in the given
year; (c) upon “remission” T2DM individuals were required
to continue to have no T2DM related claims until the end
of study period, 2015. This requirement excluded individuals
who experienced T2DM relapse. This study’s focus was only
on individuals who experienced continued “remission” and not
intermittent “remission.”
Individuals were required to have T2DM in the year 2008,
2009, 2010, and 2011 and either continue to have diabetes
(no “remission” group) or achieve “remission” (the “remission”
group) to be included in the T2DM “remission” study cohort.
T2DM relapse can occur in some individuals after “remission.”
Individuals who had relapse after first “remission” were excluded
from the study. The study cohort included a total of 10,059
patients. The “remission” group included 500 individuals and
9,559 patients in the no “remission group (Figure 1, Table A1 in
Supplementary Material).

Retinopathy

Case Definitions

This study used ICD-9 and ICD-10 diagnostic codes to
identify diabetic PVD, other aneurysm lower extremities,
PVD, foot wound and complication, claudication,
intermittent,
embolism/thrombosis
lower
extremities,
gangrene, gas gangrene, ulcer of lower limbs. An individual
with any of these clinical conditions was encoded as
having PVD.

This study used ICD-9 and ICD-10 diagnostic codes to identify
diabetic ophthalmologic disease, background retinopathy, other
retinopathy, retinal edema, cystoid macular edema/degeneration
(CSME), other retinal disorders, proliferative retinopathy, retinal
detachment, blindness, vitreous hemorrhage). An individual
with any of the above clinical conditions was encoded as
having retinopathy.

Neuropathy
This study used ICD-9 and ICD-10 diagnostic codes
to identify diabetic neuropathy, amyotrophy, cranial
nerve palsy, mononeuropathy, Charcot’s arthropathy,
polyneuropathy, neurogenic bladder, autonomic neuropathy,
gastroparesis/diarrhea, orthostatic hypotension. An individual
with any of the above clinical conditions was encoded as
having neuropathy.

Peripheral Vascular Disease (PVD)

T2DM
T2DM was identified using administrative medical and pharmacy
claims with the following criteria: at least two diagnoses of T2DM
(International Classification of Diseases, Ninth Revision, Clinical
Modification [ICD-9-CM] and/or (International Classification of
Diseases, Tenth Revision, Clinical Modification [ICD-10-CM]; at
least two prescriptions related to T2DM; at least 2 claims (medical
or pharmacy) related to T2DM. A minimum of two claims was
used in the identification of T2DM to exclude patients who were
miscoded and patients who were suspected to have T2DM but
were never formally diagnosed.

Covariates
T2DM related clinical conditions were defined using
administrative claims data as described previously using
both ICD-9 and ICD-10 codes, where applicable (20).
Demographic information (gender and race) was based
on enrollment data. T2DM related pharmacy and statins
use was determined using administrative pharmacy
claims data.

DCSI
The Diabetes Complications Severity Index (DCSI) models the
severity of diabetes complication at a specific point in the patient’s
life. DCSI is calculated as previously described (18, 20). The
final output is a patient’s score (or index value) with a range
from 0 to 13. An individual with DCSI score of 0 indicates
the patient has the least severe diabetes. This DCSI score can
be used to group the patients into high, medium and low
diabetic severity.

Statistical Analysis
Enrollment, medical and pharmacy claims data from 2008
to 2015 of more than 2.4 million patients were included
in the data aggregation. The data aggregation was done in
Hadoop (using Spark and Hive). Hadoop is an open source
software framework for distributed processing and distributed
storage of very large datasets (21). Processing was done
using Apache Spark v1.6 because of the volume of the data
included. The analytical dataset was created in a counting
process input style (22, 23). Means and frequencies to generate
patient profiles were calculated using Apache Spark v1.6.
This data was then moved into SAS 9.2. (SAS Institute
Inc., Cary NC) to calculate rate for T2DM “remission.” Cox
proportional hazard models were specified to identify the
significant variables associated with T2DM “remission” (22). The
adjusted model included demographic variables (gender, and
race), statin use, comorbidities (hypertension, hyperlipidemia,
retinopathy, neuropathy, other chronic ischemic heart disease,
other atherosclerotic cardiovascular disease and peripheral
vascular disease) and DCSI score. The level of significance for all
statistical tests was p < 0.05.

TABLE 1 | Baseline demographic and T2DM “remission” characteristics.
Characteristic

No “Remission”*
(n = 9,559)

“Remission”†
(n = 500)

P-value

Age, mean (SD),
years

72.6 (5.1)

73.7 (5.5)

<0.0001

Female sex

57.2%

62.2%

0.0273

White

7,679 (80.4)

397 (79.6)

Black

1,378 (14.4)

68 (13.6)

Others

497 (5.2)

34 (6.8)

Race/ethnicity

0.3542

Data are represented as n (%), unless otherwise mentioned. Year = 2008 * Missing data
†
in no “remission” cohort: Race (n = 5) Missing data in “remission” cohort: Race (n = 1).
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TABLE 2 | Baseline comorbidities.
Characteristic

No “Remission"* (n = 9,559)

“Remission” (n = 500)

P-value

Hypertension

8,285 (86.7)

411 (82.2)

0.0040

Hyperlipidemia

8,125 (85.0)

402 (80.4)

0.0050

Retinopathy

1,187 (12.4)

32 (6.4)

<0.0001
<0.0001

Diabetic ophthalmologic disease

830 (8.7)

17 (3.4)

Background retinopathy

392 (4.1)

<10

0.0010

Other retinopathy

138 (1.4)

<10

0.6550

Retinal edema

67 (0.7)

<10

0.0600

Cystoid macular edema/degeneration

64 (0.7)

<10

0.2010

Other retinal disorders

40 (0.4)

<10

0.9500

Proliferative retinopathy

61 (0.6)

<10

0.0730

Retinal detachment

72 (0.8)

<10

0.1550

Blindness

55 (0.6)

<10

0.0220
0.4110

21 (0.2)

<10

Neuropathy

Vitreous hemorrhage

1,801 (18.8)

68 (13.6)

0.0030

Diabetic neuropathy

1,395 (14.6)

46 (9.2)

0.0010

356 (3.7)

19 (3.8)

0.9310

<10

<10

0.1870

820 (8.6)

20 (4.0)

<0.0001

Mononeuropathy
Charcot’s arthropathy
Polyneuropathy
Neurogenic bladder

15 (0.2)

<10

0.8140

Autonomic neuropathy

78 (0.8)

<10

0.3070

Gastroparesis/diarrhea

44 (0.5)

<10

0.3950

Orthostatic hypotension

145 (1.5)

10 (2.0)

0.3930

Cerebrovascular

841 (8.8)

42 (8.4)

0.7590

Transient ischemic attack (TIA)

168 (1.8)

11 (2.2)

0.4660

Stroke

759 (7.9)

38 (7.6)

0.7840

Cardiovascular

2,925 (30.6)

174 (34.8)

0.0470

Atherosclerosis

572 (6.0)

36 (7.2)

0.2660

Other ischemic heart disease

112 (1.2)

<10

0.3900

Angina pectoris

309 (3.2)

16 (3.2)

0.9680

Other chronic ischemic heart disease

1,846 (19.3)

94 (18.8)

0.7770

Myocardial infarction

81 (0.8)

10 (2.0)

0.0080

Ventricular fibrillation, arrest

732 (7.7)

43 (8.6)

0.4410

Atrial fibrillation, arrest

11 (0.1)

<10

0.5920

Other atherosclerotic cardiovascular disease

138 (1.4)

10 (2.0)

0.3140

Old myocardial infarction

462 (4.8)

25 (5.0)

0.8650

Heart failure

503 (5.3)

34 (6.8)

0.1360

<10

<10

0.6090

Aortic aneurysm/dissection

121 (1.3)

17 (3.4)

<0.0001

Peripheral vascular disease

1,074 (11.2)

60 (12.0)

0.5980

524 (5.5)

16 (3.2)

0.0270
0.0090

Atherosclerosis, severe

Diabetic PVD
Other aneurysm, lower extremity

<10

<10

Peripheral vascular disease

807 (8.4)

51 (10.2)

0.1700

Foot wound + complication

<10

<10

0.7460
0.0190

Claudication, intermittent

623 (6.5)

46 (9.2)

Embolism/thrombosis (lower extremity)

<10

<10

0.0440

Gangrene

<10

<10

0.6470

Gas gangrene
Ulcer of lower limbs

<10

<10

0.8190

98 (1.0)

<10

0.3530

Metabolic

46 (0.5)

<10

0.3230

Ketoacidosis

16 (0.2)

<10

0.8630

Hyperosmolar

22 (0.2)

<10

0.4480

<10

<10

0.3960

Other coma

Data are expressed as n (%). Baseline year = 2011.
If the number of individuals in a cell were less than 10, the number is replaced with “< 10”.
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RESULTS
There were 10,059 people 65 years of age and older who had
T2DM in 2008, 2009, 2010 and 2011. In the study period, there
were 4.97% (95% CI, 3.05–8.00%) patients 65 years and older
(n = 500) who met the definition of T2DM “remission” in the
study cohort. At 2011, the average age of the “remission” group
was 73.7 years, while that of the non- “remission” group was 72.6
years. In the “remission” group 62.2% were female, compared to
57.2% in the non-“remission” group (Table 1).
At year 2011, the T2DM “remission” group had significantly
lower disease prevalence of hypertension, hyperlipidemia,
retinopathy (overall, diabetic ophthalmologic disease,
background retinopathy, and blindness), neuropathy (overall,
diabetic neuropathy, polyneuropathy) and diabetic peripheral
vascular disease. However, the “remission” group had higher
cardiovascular disease (overall, myocardial infarction, aortic
aneurysm and dissection) (p < 0.05) (Table 2).
In multivariate analyses, T2DM “remission” was associated
with no statin use, low diabetes complications severity index
score, no hypertension, no hyperlipidemia, no neuropathy, no
retinopathy, race (Asian/Hispanic), presence of other chronic
ischemic heart disease (IHD) and female gender (p < 0.05).
In bivariate analysis “remission” was associated with
atherosclerotic cardiovascular disease and peripheral vascular
disease (PVD). However, these associations were attenuated
in multivariate analyses and were not significant (p > 0.05)
(Figures 2, 3 and Table A2 in Supplementary Material).

CONCLUSIONS
In non-bariatric patients 65 years and older with Medicare
insurance, T2DM “remission” does occur. 4.97% (95% CI, 3.05%
- 8.00%) of patients 65 years and older met the definition
of T2DM “remission” in the study cohort. This was not
significantly different from the 2.2% (1.34–3.54%) of the 2014
Kaiser Permanente report on ≥65 year old population (13). It
is significantly different from the Look AHEAD study which
reported T2DM remission incidence of 11.5% (95% CI, 10.1–
12.8%) during the first year and 7.3% (95% CI, 6.2–8.4%)
at 4 years in the intensive lifestyle intervention group. The
percent “remission” in the present study did not differ from the
2.0% remission reported for the diabetes support and education
control condition (DSE) group (P < 0.001) (12). The study
presented here found that T2DM “remission” indeed occurs
in Medicare patients 65 years and older who did not undergo
bariatric surgery. These findings are consistent with previous
findings and challenge the widespread notion that T2DM is
irreversible in non-bariatric settings (13, 24, 25).
Consistent with the 2014 Kaiser and the Look AHEAD studies,
this study also found that the absence of hyperlipidemia was
associated with T2DM “remission.” As suggested in previous
findings, hyperlipidemia, obesity, and impaired glucose tolerance
may have a common biological pathway commonly called
metabolic syndrome. These findings provide additional evidence
of the role of managing impaired lipid metabolism to slow or
reverse T2DM progression.

Frontiers in Public Health | www.frontiersin.org

FIGURE 2 | Unadjusted Cox proportional hazard for T2DM “remission.”
ASCVD, atherosclerotic cardiovascular disease; DCSI, Diabetes complications
severity index; IHD, ischemic heart disease. Race, other, non-white and
non-African American; PVD, peripheral vascular disease.

Further, this study evaluated multiple comorbidities related
to macrovascular and microvascular comorbidities that are
typically associated with T2DM. After adjusting for covariates
this study found a number of variables associated with T2DM
“remission” that were not previously reported: no statin use; low
diabetes complications severity index score; no hypertension; no
neuropathy; no retinopathy; race (non-white and non-African
American); presence of other chronic ischemic heart disease
(IHD) and females (p < 0.05).

Gender
Globally, males are more likely to have T2DM than females
(26, 27). This trend has changed over the last 50 years. Previously,
females were more likely to have diagnosed T2DM, but in recent
years, the increasing sedentary lifestyle of males is attributed to
their increased prevalence of T2DM (28, 29). In line with these
studies the current study found that females were more likely to
have a T2DM “remission” compared to males.

6

April 2019 | Volume 7 | Article 82

Tangelloju et al.

T2DM “Remission”

FIGURE 3 | Adjusted Cox proportional hazard for T2DM “remission.” DCSI, Diabetes complications severity index; IHD, ischemic heart disease; Race, other,
non-white and non-African American.

Race

Statins

Consistent with previous studies the current study found
that Hispanics and other non-white race (excluding African
American) were more like to have a T2DM ”remission” in
the Medicare 65 years and older population (p < 0.05) (30).
This finding emphasizes the need for public health policies
to develop culturally sensitive interventions to help ameliorate
racial disparities of T2DM disease management especially in the
elderly population.

This study evaluated the role of statins on T2DM “remission”
and found that the absence of statin use is associated with
T2DM “remission” (p < 0.05). There is no previous literature
on the role of statin in T2DM “remission.” However, its role
on T2DM onset is well-established. Statin therapy is associated
with a 9% increased risk of T2DM (32). Prior investigation also
established that the level of statin potency is associated with
T2DM onset (33).

Hypertension

DCSI Score

Previous studies indicated that hypertension and T2DM
generally occur together and share several common
risk factors such as obesity, inflammation, and insulin
resistance. Hypertension and T2DM also share common
pathways such as those associated with the sympathetic
nervous system (SNS) and renin-angiotensin-aldosterone
system (RAAS) (31). The present study found that even
in Medicare patients 65 years and older population
the absence of hypertension is associated with T2DM
“remission” (p < 0.05).

The complications associated with T2DM usually develop
simultaneously or consecutively rather than independently. A
simple indicator for T2DM related complications may not
have been a sufficient measure of T2DM disease progression.
Therefore, in the present study, we used an indicator (or
score), as previously described, to quantify the severity of
diabetic complications (20, 34). This indicator is called the
DCSI, and models the severity of diabetes complication at
any given point of time in the patient’s life. Using the DCSI
score, we further analyzed the association between severity of
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One explanation of this association is that there may be a
small proportion of individuals in the study sample where the
provider takes them off their diabetic medication due to a
variety of reasons, such as the caregiver is less aggressive in
motivating patients to achieve lower HbA1c levels. Another
explanation for this association is that individuals who have
certain clinical conditions, such as those related to cardiovascular
diseases, might be on constant alert to make healthier choices,
especially due to the constant reminders that they might
be receiving from their provider, insurance agency. These
factors, and others, may be the reason why these individuals
have a different outcome compared to those without this
clinical condition.

T2DM and T2DM “remission,” and found that lower DCSI
scores (i.e., individuals who have less severe diabetes) are
associated with T2DM “remission.” This finding is important
because DCSI can thus help in stratifying individuals with
T2DM into groups based on score severity. This information
can later be used for selecting individuals into disease
management programs.

Retinopathy
Retinopathy is one of the most common microvascular damage
sites associated with T2DM. Diabetic retinopathy is a major
public health problem, with approximately one third of
T2DM patients developing some form of retinopathy (35).
The healthy function of retina depends on availability of
high amounts of oxygen, which in turn depends on intact
blood-retinal barrier. The dysglycaemia associated with T2DM
causes damage to this barrier by damaging both the inner
retinal barrier and/or causing microvascular occlusions. The
severity of such retinopathy might range from background
retinopathy to complete blindness depending on the level of
damage (36). Previous studies have recommended individuals
with T2DM to control their blood sugar, blood pressure, and
body fat to control the risk of development of advanced
retinopathy (35).
Evidence in the present study found that the absence
of any T2DM retinopathy was associated with T2DM
“remission (p < 0.05). Taken in combination with previous
recommendations, this study suggests that providers must
educate T2DM about the possibility of “remission” by lifestyle
modifications a self-incentive for enabling modified behavior,
and that they still have a chance to reverse the progression
of T2DM.

Limitations
There were several limitations to this study. First and most
important, the study does not include clinical and laboratory
findings such as physician notes and HbA1c lab results, which
would have provided a more accurate measure of T2DM
“remission.” Therefore, a small proportion of individuals could
have been asked by their doctors to stop taking T2DM medication
for a variety of unknown reasons as noted. The probability of
this occurring in the data is very low because even in those
cases the physician will probably capture the T2DM related
diagnostic code on the medical claims. Also, as with other
similar retrospective studies there is a potential for error in
information coded in the administrative data. As in other
retrospective studies it is not possible to establish causation
with such an analytic approach. The level or potency of the
T2DM medications including statins was not evaluated in
this analysis. DCSI is an unweighted composite index, and
does not independently test individual outcomes associated
with each complication associated with T2DM. Metabolic
syndrome is not included in the study due to lack of data
such as BMI and physician notes. T2DM onset age was
not available to calculate T2DM disease duration. It is not
known if an individual had bariatric surgery prior to 2008.
Individuals in the study had T2DM from 2008 to 2011 and
did not have bariatric surgery between 2008 and 2015. Typical
remission rates are greatest by year 2 of bariatric surgery (39).
Therefore, the likelihood of the observed “remission” being an
outcome of a previous bariatric surgery in these patients is
very low.
In conclusion, T2DM “remission” in patients 65 years and
older with Medicare insurance is observed in a community
setting in a small proportion of individuals who did not undergo
bariatric surgery. This study helps establish additional evidence
to the role of lifestyle intervention in T2DM progression and
provides some insights into the possibility of using behavior
and lifestyle interventions as alternate pathways for diabetes
treatment and management.
Lifestyle interventions such as increased physical activity,
low carbohydrate diet, cessation of tobacco smoking, and
reducing alcohol intake are already recommended by providers
to T2DM patients as a means to control glucose, blood
pressure and cholesterol. These study results can further
help providers discuss disease prognosis with their T2DM

Neuropathy
Neuropathy and diabetes are generally associated together. More
than 50% of T2DM individuals have neuropathy and more
than 50% of individuals with neuropathy have T2DM (37). The
study presented here found that the absence of neuropathy was
associated with T2DM “remission” in Medicare patients 65 years
and older.
Neuropathy can be associated with several causes,
including metabolic injury (hyperglycemia), compressive
injury, ischemic injuries, inflammatory and/or immune
response, and other comprehensive etiologies (38). This
study did not evaluate the specific reason associated with
neuropathy due to the lack of access to physician notes. In
spite of this limitation, this finding provides valuable insight
into designing public health interventions; for example,
individuals with T2DM and without neuropathy may be
educated about this finding to incentivize them to make behavior
and lifestyle changes.

Other Chronic IHD
IHD is the loss of elasticity and thickening of the coronary
arteries, leading to progressive arterial insufficiency. Individuals
with “other chronic IHD” were more likely to go into T2DM
“remission.” This association is not completely understood.
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